New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 29, 2014
10:39 EDTLJPC, GALTGalectin drug showed no difference from placebo, The Street reports
Galectin's (GALT) GR-MD-02 showed no difference from placebo across most efficacy biomarkers in a phase I study of nonalcoholic steatohepatitis, The Street's Adam Feuerstein reports. The stock is trading down 50% today to $7.24 while La Jolla (LJPC), which is developing a similar drug to treat NASH, is down 13%. Reference Link
News For GALT;LJPC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 12, 2014
18:29 EDTLJPCOn The Fly: After Hours Movers
Subscribe for More Information
16:18 EDTLJPCLa Jolla reports GCS-100 Phase 2 study met primary endpoint
Subscribe for More Information
16:04 EDTLJPCLa Jolla reports Q3 EPS (37c), consensus (31c)
Subscribe for More Information
November 10, 2014
15:54 EDTLJPCAmerican Society of Nephrology to hold a conference
Subscribe for More Information
09:20 EDTGALTOn The Fly: Pre-market Movers
Subscribe for More Information
08:59 EDTGALTGalectin Therapeutics GR-MD-02 Phase 1 trial meets primary endpoint
Subscribe for More Information
08:14 EDTGALTGalectin Therapeutics reports Q3 EPS (17c), consensus (27c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use